GYNAECOLOGY PATHWAY BOARD

CONSTITUTION

JULY 2014

Date for Review: July 2015
Peer Review Measures

<table>
<thead>
<tr>
<th>Measure No</th>
<th>Measure Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>14-1C-101e</td>
<td>Network Configuration</td>
</tr>
<tr>
<td>14-1C-102e</td>
<td>Network Agreed Authorised Surgeons for Diagnostic Service</td>
</tr>
<tr>
<td>14-1C-103e</td>
<td>Network Group Membership</td>
</tr>
<tr>
<td>14-1C-104e</td>
<td>Network Group Meetings</td>
</tr>
<tr>
<td>14-1C-105e</td>
<td>Work Programme &amp; Annual Report</td>
</tr>
<tr>
<td>14-1C-106e</td>
<td>Clinical Guidelines for Endometrial Cancer</td>
</tr>
<tr>
<td>14-1C-107e</td>
<td>Clinical Guidelines for Ovarian Cancer</td>
</tr>
<tr>
<td>14-1C-108e</td>
<td>Clinical Guidelines for Cervical Cancer</td>
</tr>
<tr>
<td>14-1C-109e</td>
<td>Clinical Guidelines for Vaginal and Vulval Cancer</td>
</tr>
<tr>
<td>14-1C-110e</td>
<td>Chemotherapy Treatment Algorithms</td>
</tr>
<tr>
<td>14-1C-111e</td>
<td>Patient Pathways for Endometrial Cancer</td>
</tr>
<tr>
<td>14-1C-112e</td>
<td>Patient Pathways for Ovarian Cancer</td>
</tr>
<tr>
<td>14-1C-113e</td>
<td>Patient Pathways for Cervical Cancer</td>
</tr>
<tr>
<td>14-1C-114e</td>
<td>Patient Pathways for Vaginal &amp; Vulval Cancer</td>
</tr>
<tr>
<td>14-1C-115e</td>
<td>Patient Experience</td>
</tr>
<tr>
<td>14-1C-116e</td>
<td>Clinical Outcomes Indicators &amp; Audits</td>
</tr>
<tr>
<td>14-1C-117e</td>
<td>Discussion of Clinical Trials</td>
</tr>
</tbody>
</table>

Appendices

<table>
<thead>
<tr>
<th>Appendix</th>
<th>Pathways</th>
</tr>
</thead>
<tbody>
<tr>
<td>Appendix 1</td>
<td>22</td>
</tr>
</tbody>
</table>
1. INTRODUCTION

2013/14 was a transitional year for cancer services in Greater Manchester and East Cheshire. The Greater Manchester and Cheshire Cancer Network ceased to exist in March 2013 when cancer networks nationally were amalgamated into strategic clinical networks as part of the NHS reorganisation. In Greater Manchester this coincided with the creation of Manchester Cancer, an integrated cancer system for Greater Manchester and East Cheshire.

Twenty Manchester Cancer Pathway Clinical Directors were appointed in late 2013 and took up their roles on 1st January 2014. They spent the first months in post forming their Pathway Boards, multi-professional clinical groups from across the region. These Pathway Boards are now formed and most had their first meeting in April/May of 2014.

As such, this is a transitional constitution document based on the legacy document. In July 2015 every Manchester Cancer Pathway Board will publish a full constitution alongside its annual report and work plan for the year ahead.

2. CONFIGURATION OF SERVICES (14-1C-101e)

2.1 Manchester Cancer

Manchester Cancer covers a population just over 3.3 million.

North West Sector:
Wrightington Wigan and Leigh NHS Trust
Royal Bolton Hospital NHS Foundation Trust
Salford Royal NHS Foundation Trust

North East Sector:
Pennine Acute Hospitals NHS Trust (Bury, North Manchester, Oldham, Rochdale)
Central Manchester University Hospitals NHS Foundation Trust (incorporating Trafford Hospital)

South Sector:
Tameside Acute NHS Trust
Stockport Foundation NHS Trust
University Hospital of South Manchester NHS Foundation Trust
The Christie NHS Foundation Trust
East Cheshire NHS Trust

Brain and CNS patients from Mid Cheshire NHS Trust are referred to North Staffs Cancer Network; they do not fall within the jurisdiction of Manchester Cancer for this diagnostic group.

Some chemotherapy and clinical trials will continue to be delivered from Christie Hospital, although local chemotherapy is currently available at:

- Wigan
- Bolton
- Oldham
- East Cheshire
- Mid Cheshire
2.2 Network PCT Agreed Gynaecology Cancer Referral Policy & Referral Guidelines

Primary care practitioners will refer all patients defined by the “urgent, suspicious of cancer” guidelines for gynaecology cancer to the contact point of a single stand alone diagnostic service or a gynaecology MDT as named in table 3.

Circulated via email to Primary Care Cancer Managers on Monday 18 June 2012

Nice Referral Guidelines for Suspected Cancer – Gynaecological cancer June 2005

Refer urgently patients:
- With clinical features suggestive of cervical cancer on examination. A smear test is not required before referral, and a previous negative result should not delay referral
- Not on hormone replacement therapy with postmenopausal bleeding
- On hormone replacement therapy with persistent or unexplained postmenopausal bleeding after cessation of hormone replacement therapy for 6 weeks
- Taking Tamoxifen with postmenopausal bleeding
- With an unexplained vulval lump
- With vulval bleeding due to ulceration

Consider urgent referral for patients with persistent inter-menstrual bleeding and negative pelvic examination

Refer urgently for an ultrasound scan patients:
- With a palpable abdominal or pelvic mass on examination that is not obviously uterine fibroids or not of gastrointestinal or urological origin. If the scan is suggestive of cancer, an urgent referral should be made. If urgent ultrasound is not available, an urgent referral should be made.

Investigations
- A full pelvic examination, including speculum examination of the cervix is recommended for patients presenting with any of the following:
  - Alterations in menstrual cycle
  - Intermenstrual bleeding
  - Postcoital bleeding
  - Postmenopausal bleeding
  - Vaginal discharge
- Ovarian cancer is difficult to diagnose. In patients with vague, non-specific, unexplained abdominal symptoms such as:
  - Bloating
  - Constipation
  - Abdominal pain
  - Back pain
  - Urinary symptoms
  Carry out an abdominal palpation. Also consider a pelvic examination (see NICE Ovarian Cancer Guidelines 122, extract below)

- In patients with vulval pruritus or pain, a period of “treat, watch and wait” is reasonable. Active follow-up is recommended until symptoms resolve or a diagnosis is confirmed. If symptoms persist, the referral may be urgent or non-urgent, depending on the symptoms and the degree of concern about cancer.
Ovarian cancer: The recognition and initial management of ovarian cancer
NICE clinical guideline 122, Issue date: April 2011

Page 5: Key priorities for implementation
The following recommendations have been identified as priorities for implementation.

Awareness of symptoms and signs
Carry out tests in primary care (see section 1.1.2) if a woman (especially if 50 or over) reports having any of the following symptoms on a persistent or frequent basis – particularly more than 12 times per month:

- persistent abdominal distension (women often refer to this as ‘bloating’)
- feeling full (early satiety) and/or loss of appetite
- pelvic or abdominal pain
- increased urinary urgency and/or frequency.

- Carry out appropriate tests for ovarian cancer (see section 1.1.2) in any woman of 50 or over who has experienced symptoms within the last 12 months that suggest irritable bowel syndrome (IBS), because IBS rarely presents for the first time in women of this age.

Asking the right question – first tests

- Measure serum CA125 in primary care in women with symptoms that suggest ovarian cancer (see section 1.1.1).
- If serum CA125 is 35 IU/ml or greater, arrange an ultrasound scan of the abdomen and pelvis.
- For any woman who has normal serum CA125 (less than 35 IU/ml), or CA125 of 35 IU/ml or greater but a normal ultrasound:
  - assess her carefully for other clinical causes of her symptoms and investigate if appropriate
- If no other clinical cause is apparent, advise her to return to her GP if her symptoms become more frequent and/or persistent.

Page 7-8:

1.1 Detection in primary care
Recommendations in this section update and replace recommendation 1.7.4 in ‘Referral guidelines for suspected cancer’ (NICE clinical guideline 27).

1.1.1 Awareness of symptoms and signs
1.1.1.1 Refer the woman urgently if physical examination identifies ascites and/or a pelvic or abdominal mass (which is not obviously uterine fibroids).

1.1.1.2 Carry out tests in primary care (see section 1.1.2) if a woman (especially if 50 or over) reports having any of the following symptoms on a persistent or frequent basis – particularly more than 12 times per month:

- persistent abdominal distension (women often refer to this as ‘bloating’)
- feeling full (early satiety) and/or loss of appetite
- pelvic or abdominal pain
• increased urinary urgency and/or frequency.

1.1.1.3 Consider carrying out tests in primary care (see section 1.1.2) if a woman reports unexplained weight loss, fatigue or changes in bowel habit.

1.1.1.4 Advise any woman who is not suspected of having ovarian cancer to return to her GP if her symptoms become more frequent and/or persistent.

1.1.1.5 Carry out appropriate tests for ovarian cancer (see section 1.1.2) in any woman of 50 or over who has experienced symptoms within the last 12 months that suggest irritable bowel syndrome (IBS), because IBS rarely presents for the first time in women of this age.

1.1.2 Asking the right question – first tests

1.1.2.1 Measure serum CA125 in primary care in women with symptoms that suggest ovarian cancer (see section 1.1.1).

1.1.2.2 If serum CA125 is 35 IU/ml or greater, arrange an ultrasound scan of the abdomen and pelvis.

1.1.2.3 If the ultrasound suggests ovarian cancer, refer the woman urgently for further investigation.

1.1.2.4 For any woman who has normal serum CA125 (less than 35 IU/ml), or CA125 of 35 IU/ml or greater but a normal ultrasound:

  • assess her carefully for other clinical causes of her symptoms and investigate if appropriate
  • if no other clinical cause is apparent, advise her to return to her GP if her symptoms become more frequent and/or persistent.

2.3 Network Configuration of Teams and Diagnostic Services (14-1C-102e)

The named local diagnostic gynaecology teams will carry out the diagnostic process for patients from their own catchment, referring patients to the specialist gynaecology cancer teams for specialist care. Low risk endometrial cancer may be managed by individual surgeons from the diagnostic teams provided that they are named as a member of the diagnostic service, and they attend the specialist MDT as a core member.

The three specialist gynaecology multi-disciplinary teams (SMDT) will also provide diagnostic and Unit lead services for their local population (eg. Surgical treatment of low grade endometrial cancer). There is an additional specialist team based at Christie Hospital undertaking exenterative surgery.

Primary care practitioners will refer all patients defined by the “urgent, suspicious of cancer” guidelines for gynaecological cancers to the contact point of a single named local gynaecology team as listed.
<table>
<thead>
<tr>
<th>Local Gynaecology Cancer Teams</th>
<th>CCG Population</th>
<th>CCGs in Catchment</th>
<th>Diagnostic Lead Clinician / Contact Point</th>
<th>Diagnostic services within host hospital</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bolton Hospitals NHS Trust</td>
<td>294,600</td>
<td>NHS Bolton</td>
<td>Mr Kehinde Abidogun</td>
<td>Hysteroscopy – in &amp; out patient</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Colposcopy</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Radiology guided biopsy</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>General biopsy (eg vulval)</td>
</tr>
<tr>
<td>East Cheshire NHS Trust</td>
<td>201,000</td>
<td>NHS Eastern Cheshire</td>
<td>Dr Vince Hall</td>
<td>Colposcopy, PMB Clinic,</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Hysteroscopy (inpatient &amp; outpatient)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Imaging (MR, CT, US image guided biopsy)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Laparoscopy &amp; paracentesis</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Blood tests.</td>
</tr>
<tr>
<td>Mid Cheshire NHS Trust</td>
<td>102,100</td>
<td>NHS Vale Royal NHS South Cheshire</td>
<td>Mr Murray Luckas</td>
<td>Colposcopy</td>
</tr>
<tr>
<td></td>
<td>173,200</td>
<td></td>
<td></td>
<td>Direct access PMB clinic</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>2ww dedicated Gynae clinic</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Inpatient and outpatient hysteroscopy</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Radiology biopsy</td>
</tr>
<tr>
<td>Pennine Acute Hospitals NHS Trust</td>
<td>195,000</td>
<td>NHS Bury NHS North Manchester NHS Oldham NHS HMR</td>
<td>Dr Alan Russell Mr Saad Ali Mr H Abouzeid</td>
<td>Hysteroscopy, biopsy (eg pipelle), (all Pathology inc CA125 Radiology (CT MRI)</td>
</tr>
<tr>
<td>- Bury</td>
<td>183,200</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>- NMGH</td>
<td>239,600</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>- Oldham</td>
<td>223,300</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>- Rochdale</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Stockport Foundation NHS Trust</td>
<td>299,000</td>
<td>NHS Stockport</td>
<td>Mr Suku George</td>
<td>Hysteroscopy, Colposcopy, MR, CT, USS, CT Guides Scans, Laparoscopy and Paracentesis.</td>
</tr>
<tr>
<td>Tameside Acute NHS Trust</td>
<td>240,300</td>
<td>NHS Tameside and Glossop</td>
<td>Dr Kyle Gilmour</td>
<td>Colposcopy</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Vulval disorder clinic</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Postmenopausal bleeding clinic</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>In/out patient hysteroscopy</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Ultrasound/CT/MR imaging of pelvic/ovarian masses</td>
</tr>
<tr>
<td>Wrightington, Wigan and Leigh NHS Trust</td>
<td>320,300</td>
<td>NHS Wigan Borough</td>
<td>Mr Sean Burns</td>
<td>Colposcopy</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>In/out patient hysteroscopy</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>CT guided biopsy</td>
</tr>
<tr>
<td>Specialist Gynaecology Cancer Teams</td>
<td>CCG Population</td>
<td>CCGs in Catchment</td>
<td>Lead Clinician / Contact Point</td>
<td>Diagnostic services within host hospital</td>
</tr>
<tr>
<td>------------------------------------</td>
<td>----------------</td>
<td>-------------------</td>
<td>--------------------------------</td>
<td>------------------------------------------</td>
</tr>
</tbody>
</table>
| Central Manchester University Hospitals NHS Foundation Trust | 211,800
233,100 | NHS Central Manchester
NHS Trafford | Miss Cath Holland, | Colposcopy, hysteroscopy and dedicated clinics for neoplastic and non-neoplastic vulva disorders. Specialist pathology and radiology. |
| Salford Royal Foundation Trust | 247,600 | NHS Salford | Mr Jim Wolfe | Colposcopy, PMB clinic, endometrial biopsy, hysteroscopy. USS, CT & MR |
| University Hospital of South Manchester NHS Trust | 165,100 | NHS South Manchester | Mr Mike Smith | - One Stop Rapid Access and PMB Clinic.  
- Colposcopy and Vulvoscopy Diagnostic Services for preinvasive cervical and vulval conditions.  
- Outpatient Hysteroscopy and Endometrial biopsy Service.  
- Diagnostic Imaging modalities (US, CT, MR) and Specialist Histopathology services. |

**Total** 3,329,200

The named diagnostic gynaecology teams will carry out the diagnostic process and surgical treatment for low risk endometrial and early stage cervical patients from their own catchment. All other patients should be referred onto to the Specialist MDT for discussion and treatment.

### 2.4 Network Agreed Authorised Surgeons for Diagnostic Services (14-1C-102e)

**Table 2: Local Management of Low Risk Endometrial Cancer**

<table>
<thead>
<tr>
<th>Diagnostic Team</th>
<th>Host Trust (hospital site)</th>
<th>Authorised surgeons</th>
<th>Specialist MDT link</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bolton</td>
<td>Royal Bolton NHS Trust</td>
<td>Mr K Abidogun,</td>
<td>Salford</td>
</tr>
</tbody>
</table>
| Central Manchester (Specialist MDT) | Central Manchester University Hospital NHS Foundation Trust (St Mary’s Hospital) | Prof H Kitchener
Mr R Clayton
Miss C Holland
Mr S Ali
Mr A Nysenbaum | Central Manchester |
| East Cheshire    | East Cheshire NHS Trust    | Dr V Lether
Mr V Hall | South Manchester |
### 2.5 Specialist Gynaecology Teams (also acting as local MDTs)

**Criteria for onward referral from Diagnostic Team to Specialist Gynae MDT:**

- High-risk endometrial cancer
  - Serous clear cell or GIII endometrioid endometrial cancer with or without radiological evidence of myometrial invasion
  - GI and GII endometrioid endometrial cancer with >50% myometrial invasion on MR (FIGO stage 1b on pre-operative assessment)
- Carcinoma of cervix of more than 1a1
- Suspected ovarian cancer
- Vaginal or vulval cancer
- Cyto-reductive treatment of recurrent cancer

<table>
<thead>
<tr>
<th>Specialist Gynaecology Cancer Teams</th>
<th>Lead Clinician</th>
<th>Referring Local Teams</th>
<th>Total Catchment Population</th>
<th>CCGs in Catchment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Central Manchester University Hospital NHS Trust</td>
<td>Miss Cath Holland, Consultant Gynaecologist</td>
<td>Pennine, Tameside, Trafford, Central Manchester</td>
<td>1,526,300</td>
<td>Central Manchester; Bury; HMR; North Manchester; Oldham, Tameside &amp; Glossop; Trafford</td>
</tr>
<tr>
<td>Salford Royal Foundation Trust</td>
<td>Mr Jim Wolfe, Consultant Gynaecologist</td>
<td>Wigan, Bolton, Salford</td>
<td>862,500</td>
<td>Salford, Wigan Borough, Bolton</td>
</tr>
<tr>
<td>University Hospital of</td>
<td>Mr Mike Smith, Consultant</td>
<td>Stockport, South Manchester, East</td>
<td>Trafford; South Manchester;</td>
<td></td>
</tr>
</tbody>
</table>
South Manchester NHS Trust | Gynaecologist | Cheshire, Mid Cheshire | 940,400 | Stockport, South Cheshire; Vale Royal; Eastern Cheshire
--- | --- | --- | --- | ---
**Total** | 3,329,200

**Criteria for referral from Specialist Gynae MDT to Pelvic Team:**
- Selected cases for exenterative or multidisciplinary pelvic surgery

**The Cancer Centre.**

Radiotherapy and chemotherapy will continue to be delivered from The Christie Hospital. Exenterative surgery may be managed in conjunction with The Christie inter-disciplinary pelvic surgical team in selected cases.

A new satellite radiotherapy unit opened in Oldham in March 2010 and at Salford in September 2011; however, radiotherapy for Gynae cancer will continue to be delivered at Christie Hospital.

Patients under the care of clinical or medical oncology at Christie Hospital are discussed at a weekly Christie SMDT. This meeting is attended by surgeons from the associate cancer centres. Discussions are also held about patients who are under other (non-gynae) oncology teams.
Team Relationships in the Network

**LOCAL CCG**
Refers patient for assessment

**DIAGNOSTIC GYNAE TEAMS**
(Wigan, Bolton, Bury, NMGH, Oldham, Rochdale, Trafford, Tameside, Stockport, East Cheshire, Mid Cheshire)
Also treating low risk endometrial cancer

**SPECIALIST GYNAE MDTs**
(Salford, Central Manchester, South Manchester)
Specialist teams also acts as local MDT for local population

**PELVIC TEAM AT CHRISTIE**
3. **TERMS OF REFERENCE (14-1C-104e)**

These terms of reference were agreed on 2014 by Dr Lisa Barraclough, Pathway Clinical Director for Gynaecology Cancer, and Mr David Shackley, Medical Director of Greater Manchester Cancer Services, on behalf of the Greater Manchester Cancer Services Provider Board. The terms of reference will be subject to future review.

3.1 **The Pathway Board**

The Gynaecology Cancer Pathway Board is a cancer care specific board with responsibility to improve cancer outcomes and patient experience for local people across Greater Manchester and areas of Cheshire (a catchment population of 3.2 million). This area is synonymous with the old Greater Manchester and Cheshire Cancer Network area.

The Pathway Board is led by a Pathway Clinical Director and is formed of a multidisciplinary team of clinicians and other staff from all of hospital trusts that are involved in the delivery of Gynaecology cancer care in Greater Manchester. The Pathway Board also has membership and active participation from primary care and patients representatives.

The Gynaecology Cancer Pathway Board reports into and is ultimately governed and held to account by the Greater Manchester Cancer Services Provider Board.

3.2 **Greater Manchester Cancer Services Provider Board**

The Greater Manchester Cancer Services Provider Board is responsible for the service and clinical delivery arm of Manchester Cancer, Greater Manchester’s integrated cancer system. Manchester Cancer has two other arms: research and education (see appendix for the structure of Manchester Cancer).

The Provider Board is independently chaired and consists of the Chief Executive Officers of the ten acute hospital trusts in the Greater Manchester area:

- Bolton NHS Foundation Trust
- Central Manchester University Hospitals NHS Foundation Trust
- East Cheshire NHS Trust
- Pennine Acute NHS Trust
- Salford Royal NHS Foundation Trust
- Stockport NHS Foundation Trust
- Tameside Hospital NHS Foundation Trust
- The Christie NHS Foundation Trust
- University Hospital of South Manchester NHS Foundation Trust;
- Wrightington, Wigan and Leigh NHS Foundation Trust;

The Provider Board regularly invites representatives of commissioners, the Strategic Clinical Network, and Manchester Cancer to its meetings.

3.3 **Purpose of the Pathway Board**

The purpose of the Pathway Board is to improve cancer care for patients on the Greater Manchester Gynaecology cancer pathway. Specifically, the Pathway Board aims to save more lives, put patients at the centre of care, and improve patient experience. The Board will
represent the interests of local people with cancer, respecting their wider needs and concerns. It is the primary source of clinical opinion on this pathway for the Greater Manchester Cancer Services Provider Board and Greater Manchester’s cancer commissioners.

The Pathway Board will gain a robust understanding of the key opportunities to improve outcomes and experience by gathering and reviewing intelligence about the Gynaecology cancer pathway. It will ensure that objectives are set, with a supporting work programme that drives improvements in clinical care and patient experience.

The Pathway Board will also promote equality of access, choice and quality of care for all patients within Greater Manchester, irrespective of their individual circumstances. The Board will also work with cancer commissioners to provide expert opinion on the design of any commissioning pathways, metrics and specifications.

3.4 Role of the Pathway Board

The role of the Gynaecology Cancer Pathway Board is to:

Represent the Greater Manchester Cancer Services professional and patient community for Gynaecology cancer.

Identify specific opportunities for improving outcomes and patient experience and convert these into agreed objectives and a prioritised programme of work.

Gain approval from Greater Manchester’s cancer commissioners and the Greater Manchester Cancer Services Provider Board for the programme of work and provide regular reporting on progress.

Design and implement new services for patients where these progress the objectives of commissioners and Greater Manchester Cancer Services, can be resourced, and have been shown to provide improvements in outcomes that matter to patients.

Ensure that diagnosis and treatment guidelines are agreed and followed by all teams in provider trusts, and are annually reviewed.

Ensure that all providers working within the pathway collect the pathway dataset measures to a high standard of data quality and that this data is shared transparently amongst the Pathway Board and beyond.

Promote and develop research and innovation in the pathway, and have agreed objectives in this area.

Monitor performance and improvements in outcomes and patient experience via a pathway scorecard, understanding variation to identify areas for action.

Escalate any clinical concerns through provider trusts.

Highlight any key issues that cannot be resolved within the Pathway Board itself to the Medical Director of Greater Manchester Cancer Services for assistance.

Ensure that decisions, work programmes, and scorecards involve clearly demonstrable patient participation.

Share best practices with other Pathway Boards within Greater Manchester Cancer Services.
Contribute to cross-cutting initiatives (e.g. work streams in living with and beyond cancer and early diagnosis).

Discuss opportunities for improved education and training related to the pathway and implement new educational initiatives.

Develop an annual report of outcomes and patient experience, including an overview of progress, difficulties, peer review data and all relevant key documentation. This report will be published in July of each year and will be the key document for circulation to the Provider Board. A template for this report is available so that all Pathway Boards complete the report in a similar manner.

3.5 Membership principles

All member organisations of Greater Manchester Cancer Services will have at least one representative on the Pathway Board unless they do not wish to be represented.

Provider trusts not part of Greater Manchester Cancer Services can be represented on the Pathway Board if they have links to the Greater Manchester Gynaecology cancer pathway.

All specialties and professions involved in the delivery of the pathway will be represented.

The Board will have at least one patient or carer representative within its membership.

One professional member of the Pathway Board will act as a Patient Advocate, offering support to the patient and carer representative(s).

The Board will have named leads for:

- Early diagnosis
- Pathology
- Radiology
- Surgery
- Oncology
- Specialist nursing
- Living with and beyond cancer (‘survivorship’)
- Research
- Data collection (clinical outcomes/experience and research input).

It is possible for an individual to hold more than one of these posts. The Pathway Clinical Director is responsible for their fair appointment and holding them to account.

These named leads will link with wider Greater Manchester Cancer Services Boards for these areas where they exist.

All members will be expected to attend regular meetings of the Pathway Board to ensure consistency of discussions and decision-making (meeting dates for the whole year will be set annually to allow members to make arrangements for their attendance).

A register of attendance will be kept: members should aim to attend at least 5 of the 6 meetings annually and an individual’s membership of the Pathway Board will be reviewed in the event of frequent non-attendance.

Each member will have a named deputy who will attend on the rare occasions that the member of the Board cannot.
3.6 Frequency of meetings

The Gynaecology Cancer Pathway Board will meet every two months.

3.7 Quorum

Quorum will be the Pathway Clinical Director plus five members of the Pathway Board or their named deputies.

3.8 Communication and engagement

Accurate representative minutes will be taken at all meetings and these will be circulated and then validated at the next meeting of the Board.

All minutes, circulated papers and associated data outputs will be archived and stored by the Pathway Clinical Director and relevant Pathway Manager.

The Pathway Board will design, organise and host at least one open meeting per year for the wider clinical community and local people. This meeting or meetings will include:

- An annual engagement event to account for its progress against its work programme objectives and to obtain input and feedback from the local professional community
- An annual educational event for wider pathway professionals and interested others to allow new developments and learning to be disseminated across the system

Representatives from all sections of the Greater Manchester Cancer Services professional body will be invited to these events, as well as patient and public representatives and voluntary sector partners.

An annual report will be created and circulated to the Medical Director of the Greater Manchester Cancer Services Provider Board by 31st July of each calendar year.

The agendas, minutes and work programmes of the Pathway Board, as well as copies of papers from educational and engagement events, will be made available to all in an open and transparent manner through the Greater Manchester Cancer Services website once this has been developed.

3.9 Administrative support

Administrative support will be provided by the relevant Pathway Manager with the support of the Greater Manchester Cancer Services core team. Over the course of a year, an average of one day per week administrative support will be provided.
4.  **MEMBERSHIP (14-1C-103e)**

**Table 4: Named Gynaecology Pathway Board Members and agreed roles**

<table>
<thead>
<tr>
<th>Name</th>
<th>Profession/Speciality</th>
<th>Trust</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dr Lisa Barraclough</td>
<td>Pathway Clinical Director</td>
<td>The Christie</td>
</tr>
<tr>
<td>Mr James Leighton</td>
<td>Pathway Manager</td>
<td>Manchester Cancer</td>
</tr>
<tr>
<td>Mr Kehinde Abidogun</td>
<td>Consultant Gynaecologist</td>
<td>Bolton</td>
</tr>
<tr>
<td>Dr Ann mills</td>
<td>Consultant Radiologist</td>
<td>Bolton</td>
</tr>
<tr>
<td>Dr Susan Davidson</td>
<td>Clinical Oncologist</td>
<td>Christie</td>
</tr>
<tr>
<td>Dr Andrew Clamp</td>
<td>Honorary Consultant</td>
<td>Christie</td>
</tr>
<tr>
<td>Dr Mike Smith</td>
<td>Consultant Oncologist</td>
<td>Christie</td>
</tr>
<tr>
<td>Karen Johnson</td>
<td>Nurse Clinician</td>
<td>Christie</td>
</tr>
<tr>
<td>Mr Richard Slade</td>
<td>Consultant Surgeon</td>
<td>Christie</td>
</tr>
<tr>
<td>Catherine Holland</td>
<td>Consultant Gynaecological Oncologist</td>
<td>CMFT</td>
</tr>
<tr>
<td>Rick Clayton</td>
<td>Consultant Gynaecological Oncologist</td>
<td>CMFT</td>
</tr>
<tr>
<td>Ann Lowry</td>
<td>Gynae Macmillan CNS</td>
<td>CMFT</td>
</tr>
<tr>
<td>Mr Vincent Hall</td>
<td>Consultant Obstetrician &amp; Gynaecological Surgeon</td>
<td>East Cheshire</td>
</tr>
<tr>
<td>Mrs Vanessa Hilton-Watts</td>
<td>CNS</td>
<td>East Cheshire</td>
</tr>
<tr>
<td>Mr S Ali</td>
<td>Consultant</td>
<td>Pennine</td>
</tr>
<tr>
<td>Julie Dale</td>
<td>Macmillan CNS</td>
<td>Pennine</td>
</tr>
<tr>
<td>Mr Murray Luckas</td>
<td>Consultant Gynaecologist</td>
<td>Mid Cheshire</td>
</tr>
<tr>
<td>Mrs Sally Petith</td>
<td>Gynae Oncology CNS</td>
<td>Mid Cheshire</td>
</tr>
<tr>
<td>Dr Suku George</td>
<td>Consultant Gynaecologist</td>
<td>Stockport</td>
</tr>
<tr>
<td>Jo Dzyra</td>
<td>CNS</td>
<td>Stockport</td>
</tr>
<tr>
<td>Dr Richard Hale</td>
<td>Consultant Pathologist</td>
<td>Stockport</td>
</tr>
<tr>
<td>Mr Kyle Gilmour</td>
<td>Consultant Gynaecologist</td>
<td>Tameside</td>
</tr>
<tr>
<td>Debbie Beadle</td>
<td>Gynaecology Cancer Nurse</td>
<td>Tameside</td>
</tr>
<tr>
<td>Karen Blackburn</td>
<td>Lead Manager Cancer Services</td>
<td>UHSM</td>
</tr>
<tr>
<td>Dr Manisha Kumar</td>
<td>GP Representative</td>
<td>Central Manchester CCG</td>
</tr>
<tr>
<td>Mr S Burns</td>
<td>Consultant Gynaecologist</td>
<td>WWL</td>
</tr>
<tr>
<td>Karen Blackwood</td>
<td>Gynaecology Cancer Nurse Specialist</td>
<td>WWL</td>
</tr>
</tbody>
</table>
5. NETWORK GYNAECOLOGY GUIDELINES & PATHWAYS
(14-1C-106e-14-1C-109e & 14-1C-111e – 14-1C-114e)

The Pathway Board has only been in place since spring 2014 and has not yet had the opportunity to review its clinical guidelines and patient pathways. As such, the guidelines created by the previous cancer network group have been adopted until such time as they can be reviewed and updated in the coming year.

All of the relevant documentation remains on the legacy website of the old cancer network www.gmccn.nhs.uk and will be migrated to the Manchester Cancer website over the coming months www.manchestercancer.org.

A full list of active current guidelines and their renewal dates will be produced for the updated constitution of July 2015.

5.1 PATIENT PATHWAYS

PATIENT PATHWAYS FOR ENDOMETRIAL CANCER (14-1C-111e)

PATIENT PATHWAYS FOR CERVICAL CANCER (14-1C-113e)

PATIENT PATHWAYS FOR OVARIAN/VAGINAL/VULVAL CANCER (14-1C-112e & 14-1C-114e)

6. CHEMOTHERAPY TREATMENT ALGORITHMS (14-1C-110e)

The Network Chemotherapy Group have developed chemotherapy treatment algorithms for all tumour groups which can be found using the following link. These algorithms are updated regularly with the most recent version being available on the Christie Hospital intranet site.

7. TYA PATHWAYS

7.1 The TYACN Pathway for initial management (11-1C-110e)

TEENAGE AND YOUNG ADULT PATHWAY 16-18 YEARS INCLUSIVE
(Designated and Non Designated TYA Hospitals)
TEENAGE AND YOUNG ADULT PATHWAY 19-24 YEARS

Designated TYA Hospitals

Suspected cancer
GP Referral or other route referral

Site Specific Team
(SiSpMDT)

Site-Specific Diagnostic
Pathway

SiSpMDT meeting - diagnosis and
treatment decision

TYA MDT Notified
TYA team, advice &
support to SSMDT +/-
patient/family

Jointly-agreed MDT
Decision.**
Treatment plan, clinical
trial, informed patient
choice re place of care.

TYAMDT meeting – diagnosis,
treatment & care package

INTEGRATED TREATMENT PLAN AND KEY WORKER
AGREED

Treatment in TYA designated hospital.
Coordinated by Site Specific MDT in
conjunction with PTC

Treatment in Principal Treatment Centre.
Coordinated by TYAMDT

Follow-up by SiSpMDT to integrated plan
agreed with the TYAMDT

Follow-up by TYAMDT to integrated plan
agreed with the SiSpMDT

** Jointly agreed MDT decision should not delay the start of urgent treatment
TEENAGE AND YOUNG ADULT PATHWAY 19-24 YEARS.

Non Designated TYA Hospitals

Suspected cancer
GP Referral or other route referral

Site Specific Team (SiSpMDT)

Site-Specific Diagnostic Pathway

Confirm Diagnosis

First Surgical treatment to be undertaken by designated TYA hospital

TYA MDT Notified and patient referred to PTC for treatment
7.2 The TYA Pathway for follow up on completion of first line treatment

Patient aged 16-24yrs Referred to a Site-specific MDT that is NOT based at a Principal Treatment Centre (Young People)

REFERRAL – Other route- Suspected cancer

GP REFERRAL – Suspected cancer

Site Specific Team (SiSpMDT)

Site-Specific Diagnostic Pathway

TYA team, advice & support to SSMDT +/- patient/family

SiSpMDT meeting - diagnosis and treatment decision

TYAMDT meeting – diagnosis, treatment & care package

Jointly-agreed MDT Decision

Treat in YP facility at PTC, co-ordinated by TYA MDT

Follow-up by TYA MDT to integrated plan agreed with the TYA MDT

Treat in local ‘TYA Network Partnership’ service, co-ordinated by SiSpMDT + local TYA key worker

Follow-up by SiSpMDT to integrated plan agreed with the TYA MDT

If age 19+ Patient choice - treatment in PTC or local adult service.

If age <19 Treatment in age-appropriate setting @ PTC

TYA team provide outreach support and psychosocial care to patient/family when needed and advice to local SiSpMDT and local TYA key worker

Local SiSpMDT responsible for delivery of all treatment, ongoing review, co-ordination of supportive and palliative care.

INTEGRATED TREATMENT PLAN

TYA team responsible for delivery of non-surgical oncology treatment, ongoing review, outreach support, and co-ordination of supportive and palliative care.

SiSpMDT @ PTC provide advice on treatment provide non-chemo e.g. surgery, RT. Review at SiSpMDT meeting as required
Appendix 1: Network Pathways

Patient Care Pathways – Endometrial Cancer (14-1C-111e)

Patient presents to GP with suspected gynaecological malignancy

Refer to Diagnostic Gynae Team based at:
Bolton, East Cheshire, Mid Cheshire, Pennine (Bury NMGH, Oldham, Rochdale), Stockport, Tameside, Trafford, Wigan

Refer to local patients to Specialist Gynae MDT for diagnosis and management
Salford, Central Manchester, South Manchester

- Differentiate high versus low risk
- Methods of differentiation and site of investigation according to agreed network guidelines
- Case discussion at local or specialist MDT

Confirmed low risk

Management by individual surgeon who fulfill the following criteria
- Agreed in Network Guidelines
- Named as member of the diagnostic service
- Attending as core member of local or specialist MDT
- Operating in host hospital of the diagnostic service

Confirmed high risk

Management by local or specialist MDT via teams normal care pathway

Refer to Specialist MDT for management
Patient presents to GP with suspected gynaecological malignancy or through Cervical Screening Programme

Refer to Diagnostic Gynae Team for colposcopy or biopsy
Bolton, East Cheshire, Mid Cheshire, Pennine (Bury NMGH, Oldham, Rochdale), Stockport, Tameside, Trafford, Wigan

SCC stage 1A1 or above: histology review by histopathology core member of specialist MDT.

Where the specialist MDT considers a microinvasive squamous cancer is very low risk and indicates that a cone biopsy alone is adequate management the patients may be managed by the local team

No further treatment

Complete excision biopsy by diagnostic team: No further treatment

Incomplete excision biopsy: Management by specialist team

Management by Specialist MDT
Salford, Central Manchester, South Manchester

SCC stage 1A2 or above, or non-squamous cancer

Refer to local patients to Specialist Gynae MDT for colposcopy or biopsy
Salford, Central Manchester, South Manchester
Patient presents to GP with suspected gynaecological malignancy

Refer to Diagnostic Gynae Team
Bolton, East Cheshire, Mid Cheshire,
Pennine (Bury NMGH, Oldham,
Rochdale), Stockport, Tameside,
Trafford, Wigan

Refer to local patients to Specialist Gynae MDT for diagnosis
Salford, Central Manchester, South Manchester

Management by Specialist MDT
Network Agreed Management Pathway for Gynaecological Cancer

Possible cervical cancer

- Patient
- GP
- Cervical screening
- GP

Possible ovarian, endometrial, vaginal or vulval cancer

- Patient
- GP
- Referral booking
- Management Service

CANCER CENTRE

- Appt made & agreed with patient
- Colposcopy/biopsy
- Cervical
  - Stage Ia1
  - > stage Ia2

- Endometrial cancer
  - Stage 1a Grade 1 or 2
  - Stage 1a Grade 3, Stage Ib, > stage II

- Diagnosis
  - GP informed within 24 hours of patient being told

- Ovarian, vaginal or vulval cancer (all patients)

CANCER UNIT

- Surgery at Cancer Unit
- Specialist multi-professional gynaecological oncology team
- Active monitoring
- Surgery
- Oncology
- Palliative Care
- Inform out of hours care
- Terminal care +LCP
- Bereavement care *
- Death

COMMUNITY

- GP follows local guidelines on re-referral if symptoms persist

Key
- *patient information
- +Health professional communication